» Articles » PMID: 16191199

Hepatitis B Virus: Inactive Carriers

Overview
Journal Virol J
Publisher Biomed Central
Specialty Microbiology
Date 2005 Sep 30
PMID 16191199
Citations 39
Authors
Affiliations
Soon will be listed here.
Abstract

Inactive carriers forms the largest group in chronic HBV infected patients. Around 300 million people are inactive carriers The inactive HBsAg carrier state is diagnosed by absence of HBeAg and presence of anti-HBe, undetectable or low levels of HBV DNA in PCR-based assays, repeatedly normal ALT levels, and minimal or no necroinflammation, slight fibrosis, or even normal histology on biopsy. Inactive cirrhosis may be present in patients who had active liver disease during the replicative phase of infection. The prognosis of the inactive HBsAg carrier state is usually benign. Long-term follow- up (up to 18 years) of these carriers has indicated that the vast majority show sustained biochemical remission and very low risk of cirrhosis or hepatocellular carcinoma (HCC). Rarely, patients, even noncirrhotics, may develop liver cancer during the inactive HBsAg carrier state. In addition, approximately 20 to 30% of persons in the inactive HBsAg carrier state may undergo spontaneous reactivation of hepatitis B during follow-up. Multiple episodes of reactivation or sustained reactivation can cause progressive hepatic damage and even hepatic decompensation.

Citing Articles

A Comprehensive Analysis of Inactive Hepatitis B Infection in a Cohort of Omani Patients.

Al Shuaili H, Al Mashikhi B, Al Sinani A, Al Busafi S Oman Med J. 2025; 39(5):e673.

PMID: 40060980 PMC: 11890281. DOI: 10.5001/omj.2024.104.


Peripheral Blood CD4/CD8 T Cell Ratio Predicts HBsAg Clearance in Inactive HBsAg Carriers Treated with Peginterferon Alpha.

Wu F, Liu C, He L, Wang Y, Zhang X, Li M J Clin Transl Hepatol. 2025; 13(2):130-142.

PMID: 39917468 PMC: 11797822. DOI: 10.14218/JCTH.2024.00240.


Liver histology pattern of young patients with inactive chronic hepatitis b virus infection from a hospital in South West Nigeria.

Oje M, Kolawole O, Ijarotimi O, Adekanle O, Jegede O, Ndububa D BMC Gastroenterol. 2024; 24(1):438.

PMID: 39604871 PMC: 11603992. DOI: 10.1186/s12876-024-03501-7.


Dual Detection of Hepatitis B and C Viruses Using CRISPR-Cas Systems and Lateral Flow Assay.

Shahni S, Albogami S, Azmi I, Pattnaik B, Chaudhuri R, Dev K J Nucleic Acids. 2024; 2024:8819834.

PMID: 39399398 PMC: 11470818. DOI: 10.1155/2024/8819834.


Impact of hepatitis virus infection on inpatient outcomes of acute pancreatitis: A population-based study.

Lai H, Hung H, Lin C Medicine (Baltimore). 2023; 102(22):e33952.

PMID: 37266621 PMC: 10238054. DOI: 10.1097/MD.0000000000033952.


References
1.
Beasley R . Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer. 1988; 61(10):1942-56. DOI: 10.1002/1097-0142(19880515)61:10<1942::aid-cncr2820611003>3.0.co;2-j. View

2.
Di Marco V, Lo Iacono O, Camma C, Vaccaro A, Giunta M, Martorana G . The long-term course of chronic hepatitis B. Hepatology. 1999; 30(1):257-64. DOI: 10.1002/hep.510300109. View

3.
Bortolotti F, Jara P, Crivellaro C, Hierro L, Cadrobbi P, Frauca E . Outcome of chronic hepatitis B in Caucasian children during a 20-year observation period. J Hepatol. 1998; 29(2):184-90. DOI: 10.1016/s0168-8278(98)80002-0. View

4.
Tassopoulos N, Volpes R, Pastore G, Heathcote J, Buti M, Goldin R . Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group. Hepatology. 1999; 29(3):889-96. DOI: 10.1002/hep.510290321. View

5.
Fattovich G, GIUSTINA G, Quero C, Mas A, Olivotto P, Solinas A . Delayed clearance of serum HBsAg in compensated cirrhosis B: relation to interferon alpha therapy and disease prognosis. European Concerted Action on Viral Hepatitis (EUROHEP). Am J Gastroenterol. 1998; 93(6):896-900. DOI: 10.1111/j.1572-0241.1998.00272.x. View